You're one step closer to unlocking our suite of comprehensive and robust tools.
Fill out the form so we can connect you to the right person.
European Medicines Agency committee recommends Pfizer's arthritis drug
Street Talk Episode 51 - Goldman Talks Libor Transition, Recent SOFR Volatility
ChangePays Although Still Underrepresented Women in the C Suite are Driving Profitability
Cable Nets For Kids Enjoy Wide Carriage On Skinny Bundles
Power Forecast Briefing: Fleet Transformation, Under-Powered Markets, and Green Energy in 2018
The European Medicines Agency's Committee for Medicinal Products for Human Use made a recommendation in favor of Pfizer Inc.'s Lifmior to treat rheumatoid arthritis and other forms of arthritis, as well as plaque psoriasis.
The drug is identical to Amgen's Enbrel, which was authorized in the EU in 2000. Lifmior is still subject to approval by the European Commission.